Edition:
United States

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

56.69USD
22 Sep 2017
Change (% chg)

$-0.33 (-0.58%)
Prev Close
$57.02
Open
$56.95
Day's High
$57.92
Day's Low
$56.67
Volume
34,469
Avg. Vol
40,971
52-wk High
$57.92
52-wk Low
$41.40

Latest Key Developments (Source: Significant Developments)

Anika announces appointment of Joseph Darling as president
Thursday, 27 Jul 2017 08:05am EDT 

July 27 (Reuters) - Anika Therapeutics Inc :Anika announces appointment of joseph darling as president.Anika therapeutics - co's ceo dr. Charles h. Sherwood who served as president, plans to transition role to darling, while continuing tenure as ceo.  Full Article

Anika reports Q2 earnings per share $0.76
Wednesday, 26 Jul 2017 04:05pm EDT 

July 26 (Reuters) - Anika Therapeutics Inc :Anika reports strong second quarter 2017 financial results.Q2 earnings per share $0.76.Q2 revenue $33.5 million versus I/B/E/S view $27.2 million.Q2 earnings per share view $0.44 -- Thomson Reuters I/B/E/S.Anika Therapeutics Inc says company plans to expand into India, Australia, and New Zealand over next six to nine months.Anika Therapeutics Inc says receiving regulatory approval for Monovisc in India for treatment of pain associated with osteoarthritis of all human synovial joints.  Full Article

Anika announces $5 mln milestone payment from U.S. commercial sales of Monovisc
Monday, 17 Jul 2017 04:05pm EDT 

July 17 (Reuters) - Anika Therapeutics Inc :Anika announces $5 million milestone payment from U.S. Commercial sales of Monovisc.Sees Q2 2017 revenue up 23 to 26 percent.Anika - Milestone payment triggered by Monovisc achieving $100 million in U.S. end-user sales within consecutive 12-month period at end of June.Anika Therapeutics Inc - Company will recognize milestone payment as revenue in Q2 of 2017.Q2 revenue view $27.2 million -- Thomson Reuters I/B/E/S.  Full Article

Anika Therapeutics expects to complete supplemental phase III trial of CINGAL in 2018
Thursday, 25 May 2017 01:30pm EDT 

May 25 (Reuters) - Anika Therapeutics Inc ::Anika announces first patient enrolled in supplemental phase III trial of CINGAL for the treatment of knee pain associated with osteoarthritis.Anika expects to complete supplemental phase III trial in 2018 and anticipates FDA approval in following year.  Full Article

Anika Therapeutics reports Q1 earnings per share $0.37
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Anika Therapeutics Inc :Anika reports first quarter 2017 financial results.Q1 earnings per share $0.37.Q1 revenue $23.4 million versus i/b/e/s view $23.9 million.Q1 earnings per share view $0.38 -- Thomson Reuters I/B/E/S.  Full Article

Anika Q3 earnings per share $0.59
Wednesday, 26 Oct 2016 04:05pm EDT 

Anika Therapeutics Inc - : Anika reports third quarter 2016 financial results . Q3 earnings per share $0.59 . Q3 revenue $25.8 million versus I/B/E/S view $26.6 million .Q3 earnings per share view $0.47 -- Thomson Reuters I/B/E/S.  Full Article

Anika Q2 earnings per share $0.57
Wednesday, 27 Jul 2016 04:05pm EDT 

Anika Therapeutics Inc : Anika reports second quarter 2016 financial results . Q2 earnings per share $0.57 . Q2 revenue $26.6 million versus I/B/E/S view $24.7 million .Q2 earnings per share view $0.44 -- Thomson Reuters I/B/E/S.  Full Article

Anika Therapeutics announces Canadian launch of cingal
Thursday, 19 May 2016 09:05am EDT 

Anika Therapeutics Inc : Announces Canadian launch of cingal for the treatment of pain associated with osteoarthritis of the knee .Cingal will be marketed and sold in Canada by Pendopharm, a division of Pharmascience Inc, a Quebec-based pharmaceutical company.  Full Article

Anika Therapeutics announces $25 million accelerated share repurchase
Wednesday, 24 Feb 2016 04:10pm EST 

Anika Therapeutics:Will enter into an accelerated share repurchase program to repurchase $25 million of its outstanding common stock.Company will enter into an accelerated stock repurchase agreement with Morgan Stanley & Co. LLC pursuant to a Fixed Dollar Accelerated Share Repurchase Transaction to purchase $25 million of shares of its common stock.  Full Article

Anika Therapeutics Inc announces health canada approval of CINGAL for the treatment of pain associated with osteoarthritis of the knee
Tuesday, 3 Nov 2015 09:00am EST 

Anika Therapeutics Inc:Announces health canada approval of CINGAL for the treatment of pain associated with osteoarthritis of the knee.  Full Article

BRIEF-Kayne Anderson Rudnick Investment Management Llc reports 11.49 pct passive stake in Anika Therapeutics Inc as of August 08, 2017 - SEC filing

* Kayne anderson rudnick investment management llc reports 11.49 percent passive stake in anika therapeutics inc as of august 08, 2017 - sec filing Source text - (http://bit.ly/2fqZxZ8) Further company coverage: